Clinical Trials Browser

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT02331498 2025-05-20

PAZOGLIO

Phase 1/2 Recruiting

51 enrolled

CNS

Glioblastoma

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

31 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1 Completed

28 enrolled

BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

NCT03275558 2018-07-19

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Phase 1 Withdrawn

CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Phase 2 Terminated

7 enrolled 8 charts

CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Phase 1 Withdrawn

CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00929903 2013-09-30

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Phase 1 Completed

55 enrolled

CNS

Optic Nerve Glioma